Actively Recruiting
Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-02-07
1000
Participants Needed
1
Research Sites
1043 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The BOMASH study is a single-center, prospective/retrospective observational study without pharmacological interventions. It will include all patients diagnosed with Metabolic-Associated Steatotic Liver Disease (MASLD/MASH), whether newly diagnosed or previously identified at the center during follow-up or as part of routine diagnostic and therapeutic care. The aim of the study is to identify predictive factors related to the prognosis of patients with metabolic liver disease (MASLD/MASH). Specifically, the study seeks to uncover biomarkers that can identify individuals at risk of requiring a liver transplant or developing HCC.
CONDITIONS
Official Title
Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients with a diagnosis of MASLD, established according to the most recent published guidelines (EASL, EASD, EASO)
- Age �38 years
- Patients requiring liver biopsy for diagnostic purposes, as indicated by the most recent published guidelines (EASL, EASD, EASO)
You will not qualify if you...
- No exclusion criteria.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
Research Team
F
Fabio Piscaglia, MD
CONTACT
F
Federico Ravaioli, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here